X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Stemson is developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles. It is being evaluated in preclinical studies for the treatment of androgenetic alopecia, scarring alopecia & chemo-induced alopecia.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
Stemson’s Induced Pluripotent Stem Cell (iPSC) based technology is capable of producing the cell types required to initiate hair follicle growth and have been successfully tested in small animal models.
Lead Product(s): Human Induced Pluripotent Stem Cells
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Genoa Ventures
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
